The Campaign for Safe Cosmetics
This article was originally published in The Rose Sheet
Executive Summary
Estee Lauder should remove phthalates - chemicals linked to cancer and reproductive disorders - from all of its products in every market, consumer advocacy organization states in a Feb. 7 release. CFSC points to Winter 2007 Consumer Reports which identified Lauder's Aveda Love Pure-Fume Essence, Clinique Happy and Estee Lauder Beautiful as containing phthalates DEP and DEHP, though the ingredients were not listed on the packaging. While DEHP is banned from cosmetics in Europe, both the European and U.S. samples of Happy and Beautiful were found to contain the chemical. The organization is behind a pledge to cleanse cosmetics of all ingredients banned overseas for associated health risks. More than 500 companies have signed on; Estee Lauder is not one of them (1"The Rose Sheet" Feb. 5, 2007, In Brief)...
You may also be interested in...
Campaign for Safe Cosmetics
More than 500 companies have signed a pledge to eliminate toxic ingredients from their products, the Campaign for Safe Cosmetics announces Jan. 25. The pledge was released in 2004 and requires signers to replace cosmetic ingredients linked to hormone disruption, birth defects, cancer and other health risks within three years. The pledge additionally calls for companies to meet European Union bans on chemicals linked to cancer and birth defects, conduct an inventory of all ingredients to determine whether they pose a risk and issue public reports on their efforts to meet these goals. To date, major companies such as Estee Lauder, Revlon, Avon, OPI and Procter & Gamble have not signed the compact, the campaign states. Recent signers include Intelligent Nutrients, Mi Amore Skincare and Crush Groove Cosmetics, according to the campaign...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.